摘要
目的:分析碳酸酐酶IX(CA IX)在乳腺浸润性导管癌组织中的表达及其与临床病理因素的关系。方法:采用免疫组织化学方法检测90例乳腺浸润性导管癌CA IX的表达,比较它们在不同分子分型组织中表达的差异,并分析乳腺浸润性导管癌CA IX的表达与患者年龄,组织学分级及ER、PR、HER-2受体的表达状况等主要病理学特征的关系。结果:CA IX蛋白在乳腺浸润性导管癌的肿瘤细胞上明显高表达,在III-IV期明显高表达于I期和II期(P<0.05),CA IX蛋白表达在三阴性型、HER-2型和Luminal型呈逐步明显降低(P<0.05)。结论:CA IX蛋白特异性高表达于乳腺癌组织上,且肿瘤恶性程度越高,其表达越高。CA IX在乳腺浸润性导管癌的发生发展过程中扮演着重要角色,可能参与肿瘤细胞的增殖、浸润。
Objective:To analyze the expression of carbonic anhydrase IX(CA IX)in breast invasive ductal carcinoma and its relationship with clinicopathological factors.Methods:Immunohistochemistry was used to detect the expression of CA IX in 90 cases of breast invasive ductal carcinoma,and the difference of CA IX expression in different molecular typing tissues was compared.The relationship between CA IX expression of breast invasive ductal carcinoma and patients’age,histological grade and expression of ER,PR,HER-2 receptor was analyzed.Results:The expression of CA IX protein was significantly higher in the tumor cells of breast invasive ductal carcinoma,and it was significantly higher in stage III-IV than in stage I and II(P<0.05).CA IX proteien expreasison gradually decreased in triple negative,HER-2 type and Luminal type(P<0.05).Conclusion:CA IX protein is highly expressed in breast cancer,and the more malignant the tumor is,the higher the expression is.CA IX plays an important role in the occurrence and development of breast invasive ductal carcinoma,which may be involved in the proliferation and infiltration of tumor cells.
作者
段佳佳
赵宏颖
王莹
刘敏
孙劲文
Duan Jiajia;Zhao Hongying;Wang Ying;Liu Min;Sun Jinwen(Department of General Surgery Oncology,China Emergency General Hospital,Beijing 100028,China;Department of Pathology,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China;Department of Radiology,China-Japan Friendship Hospital,Beijing 100029,China.)
出处
《现代肿瘤医学》
CAS
2020年第17期2974-2977,共4页
Journal of Modern Oncology
基金
国家自然科学基金青年项目(编号30900364)
2019年度首都医科大学本科生科研创新项目(编号:XSKY2019173)。
关键词
CA
IX
免疫组织化学
浸润性导管癌
临床病理因素
CA IX
immunohistochemistry
invasive ductal carcinoma
clinicopathological factors